Primary analysis of a phase 1b multicenter trial to evaluate safety and efficacy of talimogene laherparepvec (T-VEC) and ipilimumab (ipi) in previously untreated, unresected stage IIIB-IV melanoma.
Igor Puzanov
Consultant or Advisory Role - Amgen
Mohammed M. Milhem
No relevant relationships to disclose
Robert Hans Ingemar Andtbacka
Consultant or Advisory Role - Amgen
David R. Minor
Consultant or Advisory Role - GlaxoSmithKline
Honoraria - Bristol-Myers Squibb; GlaxoSmithKline
Omid Hamid
Consultant or Advisory Role - Amgen
Research Funding - Amgen
Ai Li
Employment or Leadership Position - Amgen
Stock Ownership - Amgen
Michael Chastain
Employment or Leadership Position - Amgen
Stock Ownership - Amgen
Kevin Gorski
Employment or Leadership Position - Amgen
Stock Ownership - Amgen
Abraham Anderson
Employment or Leadership Position - Amgen
Stock Ownership - Amgen
Ari M. Vanderwalde
Employment or Leadership Position - Amgen
Jeffrey Chou
Employment or Leadership Position - Amgen
Howard Kaufman
Consultant or Advisory Role - Amgen